Clinical trial · Interventional
Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects
Pharmacokinetics and Metabolism of [14C] BMS-690514 in Healthy Male Subjects
NCT00578916CI-TRIAL-00001630completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine how the human body processes and eliminates the drug (BMS-690514.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EVRI (BMS-690514) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: EVRI (BMS-690514)
Primary outcomes (1)
- measure
- Single dose pharmacokinetics of BMS-690514 and radioactivity in plasma and urine
- timeFrame
- measured for 10 days post-dose
Secondary outcomes (1)
- measure
- Determination of biotransformation profiles and recorded adverse events
- timeFrame
- for 10 days post-dose
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Healthy male subjects * Body mass index (BMS) of 18 - 30 kg/m², inclusive Exclusion Criteria: * Radiation exposure from diagnostic X-rays (except dental X-rays) in the last year or from clinical trials in the last 5 years
References
Publications (0)
Data not yet available
No reference posted for this study.